GlassScriptPhysician profile
Regina Chimileski
NPI 1598479586
$8,135.13
in general payments reported to CMS, 2019-2025
24 companies · $2,647 in 2025
The $2,647 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,850 · 2024: $3,639 · 2025: $2,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,859 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,859.49 |
| Education | $275.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,849.59 | 2023-2025 | |
| Incyte Corporation | $852.80 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $772.03 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $588.10 | 2023-2025 | Tremfya |
| Ucb, INC. | $581.82 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $536.34 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Pfizer INC. | $516.74 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $349.81 | 2023-2025 | Zoryve |
| Amgen INC. | $306.12 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $244.31 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $243.75 | 2023-2025 | |
| Dermavant Sciences, INC. | $236.35 | 2023-2024 | Vtama |
| Lilly USA, LLC | $205.37 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $198.77 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $146.17 | 2023-2025 | Nemluvio, Aklief |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $104.60 | 2023-2024 | Seysara, Klisyri |
| Regeneron Healthcare Solutions, INC. | $81.42 | 2024 | Libtayo |
| Verrica Pharmaceuticals INC. | $74.44 | 2023-2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.69 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.12 | 2025 | Cabtreo |
| Organon LLC | $50.66 | 2025 | Vtama |
| Sandoz INC. | $41.51 | 2025 | Hyrimoz |
| Botanix Sb INC | $18.12 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $4.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Chimileski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.